Pharma Trend
  • Pharma Trend
  • Pharma Award
    • Golden Tablet
    • Most innovative Product
    • Honorary Award
  • Pharma Ranking
  • Impressions
  • Sponsors & Partners
  • News
    • Gastroenterologists
    • Industry
    • Pain Therapists
    • Urologists

Chiesi ranks 10th in Pharma Trend Ranking 2022

October 7, 2022 by Editorial staff

Chiesi is ranked 10th in the multispecialist “Best Pharmaceutical Companies Germany” 2022 ranking in the category “Large individual, medium-sized and international companies”. Infectopharm, Gedeon Richter, ALK-Abelló and Exeltis placed first in this year’s Pharma Trend study. Chiesi has made a name for itself as a research company, especially in the field of respiratory diseases.

Chiesi: AIR, RARE and CARE

Chiesi Farmaceutici S.p.A., headquartered in Parma, is a research-based, international pharmaceutical and healthcare company. The Group currently employs 6,440 people in a global organisation that includes 30 subsidiaries, seven research centres in Italy, France, the United States, Canada, China, the United Kingdom and Sweden, three production sites in Italy, France and Brazil, and representative offices in 90 countries.

Chiesi is dedicated to three therapeutic areas: AIR, products and services related to respiratory diseases; RARE, the treatment of patients with rare and very rare diseases; CARE, products and services for specialist care and self-medication.

The Chiesi Group generated revenues of €2.42 billion in 2021 with strong international growth of 8.6%. Half of these revenues were generated by leading products in the AIR segment. Chiesi developed products mainly for chronic obstructive pulmonary disease (COPD) and bronchial asthma, such as Budiair®, Forair®, Foster®, Inovair®, Sanasthmax® and Trimbow®, including the necessary inhalation and nebulisation systems. The respiratory R&D pipeline was expanded through a partnership with UCB, including the commercialisation of a clinical-stage monoclonal antibody, transglutaminase 2, in fibrosis diseases.

In addition to the core area of respiratory diseases, Chiesi is increasingly involved in neonatology (Curosurf® for neonatal respiratory distress syndrome), transplantation medicine (Envarsus® for immunosuppression) and biotechnology (construction of a biotech centre of excellence plant in Parma). A separate business unit, Chiesi Global Rare Diseases, is dedicated to rare diseases (including Ferriprox® for iron overload, Raxone® for optic neuropathy); it generates about 11% of total sales.

Chiesi’s Research and Development Centre in Parma employs 361 people. Expenditure on research and development amounted to 478.8 million euros in 2021, i.e. just under 20% of turnover.

The German subsidiary, Chiesi GmbH, based in Hamburg, employs around 375 people. As the second-largest sales company in the Chiesi Group, it generated sales of 308.7 million euros in 2021.

Chiesi Farmaceutici S.p.A. has been recognised as a Top Employer® in eight countries worldwide: Italy, Brazil, Germany, Greece, Poland, Russia, the UK and the USA. More than 54 per cent of employees worldwide are female and almost two-thirds work in research and development.

About the award ceremony

The awards were announced on 13 September 2022 at the Deutsches Museum in Munich. The keynote speech was given by the patron of the event, the Bavarian Minister of Health Klaus Holetschek, Bavarian State Ministry of Health and Care. The festive awards ceremony was hosted by TV presenter Tamara Sedmak (Sat 1, n-tv, N24).

Pharma Trend - The market research on innovation and sustainability

The basis for the ranking and the awards is the Pharma Trend benchmark study, which has been conducted annually in the Rx category among physicians in Germany since 2000 and since 2018 also in the OTC and Orphan Drugs categories, and since 2019 also in the Specialty Care category on behalf of the PharmaBarometer magazine (https://pharmabarometer.de/pharmabarometer/). In 2021, the study was expanded to include the categories “Diagnostics” and “Digital Health Applications”. With the expansion of Pharma Trend, companies in pharmaceuticals and medical technology are assessed on innovation and sustainability via their most important stakeholders – doctors, pharmacists and patients. This year, Pharma Trend was conducted online with 700 physicians, including allergists, general practitioners, dermatologists, gynaecologists, oncologists/haematologists, paediatricians and urologists, as well as 100 pharmacists and 600 patients.

Further information on Pharma Trend and the report volumes at https://pharma-trend.com/en/

Related posts:

  1. Bencard ranks 6th in Pharma Trend Ranking 2022
  2. Astellas ranks 10th in Pharma Trend Ranking 2022
  3. HAL Allergy ranks 7th in Pharma Trend Ranking 2022
  4. Incyte ranks 9th in Pharma Trend Ranking 2022
Posted in: Allgemein Tagged: Ranking

Patronage

Melanie Huml, Minister of Bavarian State Ministry of Health and Care

Pharma Trend Image and Innovation Award

The survey of innovation and sustainability in pharmaceutical companies.

  • Deutsch
  • English

In the News

  • EY US Announces Nabiha Saklayen of Cellino as an Entrepreneur Of The Year® 2025 New England Award Winner June 12, 2025
  • Presidio Medical™ Receives IDE Approval for Ultra Low Frequency (ULF™) Neuromodulation Clinical Study and Appoints Dimas Jiménez as Chief Financial Officer June 12, 2025
  • Bristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD™ Agents and BCL6 Ligand-Directed Degrader at EHA 2025 June 12, 2025
  • SpikImm and SATT Conectus Sign a Definitive Licensing Agreement for Prophylactic Treatment Against the BK Virus, to Prevent Severe Complications in Transplant Patients June 12, 2025
  • Establishment Labs Hosting Investor Day on June 12 June 12, 2025

Partners




Bio M ist Partner der Goldenen Tablette



Media Partnerships



Esanum ist Medienpartner der Goldenen Tablette







Sponsors & Partners:


ashfield
lucky7even is sponsor of Pharma Trend
Harris Interactive is partner of Pharma Trend
PharmaBarometer
Dorothea Küsters Life Science Communications
EQS-Group is sponsor of Pharma Trend
Esanum
MCC Logo
JJ Sustainability is sponsor of Pharma Trend
Healthcare Marketing Logo weiß
Bio-M
Gesdat Logo
tiny web is sponsor of Pharma Trend

Copyright © 2023 Eurecon Verlag GmbH

Imprint   |   Privacy Statement